Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis

Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis

BackgroundWhile immune checkpoint inhibitors (ICIs) are a beacon of hope for non-small cell lung cancer (NSCLC) patients, they can also cause adverse events, including checkpoint inhibitor pneumonitis (CIP). Research shows that the inflammatory immune microenvironment plays a vital role in the devel...

Full description

Bibliographic Details
Main Authors:	Xinqing Lin, Jiaxi Deng, Haiyi Deng, Yilin Yang, Ni Sun, Maolin Zhou, Yinyin Qin, Xiaohong Xie, Shiyue Li, Nanshan Zhong, Yong Song, Chengzhi Zhou
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-01-01
Series:	Frontiers in Immunology
Subjects:	checkpoint inhibitor pneumonitis immune infiltration immune microenvironment aberrant pathway activation immune check inhibitor (ICI)
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2021.818492/full

Similar Items

Peripheral Blood Biomarkers for Early Diagnosis, Severity, and Prognosis of Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer
by: Xinqing Lin, et al.
Published: (2021-07-01)

Epidemiological analysis of real-world immune checkpoint inhibitor-related pneumonitis in Chinese patients with lung cancer
by: WU Jianhui, CHU Xiangling, WANG Liqiang, LIN Xinqing, XIE Xiaohong, XIE Mengqing, ZHAO Jing, DENG Haiyi, YANG Yilin, QIU Guihuan, ZHOU Maolin, SUN Ni, LI Ru, CHEN Ying, DENG Jiaxi, ZENG Chen, PAN Bolin, QIN Yinyin, LIU Ming, SU Chunxia, ZHOU Chengzhi
Published: (2022-06-01)

Proposed clinical phases for the improvement of personalized treatment of checkpoint inhibitor–related pneumonitis
by: Chengzhi Zhou, et al.
Published: (2022-07-01)

Differentiation of COVID-19 Pneumonitis and ICI Induced Pneumonitis
by: Daphne W. Dumoulin, et al.
Published: (2020-10-01)

Cellular analysis of bronchoalveolar lavage fluid to narrow differential diagnosis of checkpoint inhibitor-related pneumonitis in metastatic melanoma
by: Sabino Strippoli, et al.
Published: (2020-12-01)

Comprehensive Pneumonitis Profile of Thoracic Radiotherapy Followed by Immune Checkpoint Inhibitor and Risk Factors for Radiation Recall Pneumonitis in Lung Cancer
by: Xiaotong Lu, et al.
Published: (2022-06-01)

Comparison of pneumonitis risk between immunotherapy alone and in combination with chemotherapy: an observational, retrospective pharmacovigilance study
by: Huixia Li, et al.
Published: (2023-04-01)

Recent Advances in Immune Checkpoint Inhibitor-associated Pneumonitis
by: CHEN Shuangqing, et al.
Published: (2022-10-01)

Clinical Diagnosis and Treatment Recommendations for the Pneumonitis Associated with Immune Checkpoint Inhibitor
by: Hanping WANG, et al.
Published: (2019-10-01)

Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor
by: Wenxian Wang, et al.
Published: (2022-12-01)

Imaging features of toxicities associated with immune checkpoint inhibitors
by: Babina Gosangi, et al.
Published: (2022-01-01)

Identification and prediction of immune checkpoint inhibitors-related pneumonitis by machine learning
by: Li Gong, et al.
Published: (2023-06-01)

HSV-pneumonitis in a patient with lung cancer receiving check point inhibitors – a case report
by: Johannes Sumer, et al.
Published: (2021-01-01)

Immune checkpoint inhibitor-related pneumonitis: research advances in prediction and management
by: Mei-Xi Lin, et al.
Published: (2024-02-01)

Dosimetric Risk Factors for Acute Radiation Pneumonitis in Patients With Prior Receipt of Immune Checkpoint Inhibitors
by: Jianping Bi, et al.
Published: (2022-01-01)

Insights into Potential Pathogenesis and Treatment Options for Immune-Checkpoint Inhibitor-Related Pneumonitis
by: Hiroyuki Ando, et al.
Published: (2021-10-01)

Case Report: Fatal Multiorgan Failure and Heterochronous Pneumonitis Following Pembrolizumab Treatment in a Patient With Large-Cell Neuroendocrine Carcinoma of Lung
by: Xiaohong Xie, et al.
Published: (2021-01-01)

Coexistence of Immune Checkpoint Inhibitor-Induced Autoimmune Diabetes and Pancreatitis
by: Amy L. Zhang, et al.
Published: (2021-04-01)

Association of Clinical and Radiological Features with Disease Severity of Symptomatic Immune Checkpoint Inhibitor-Related Pneumonitis
by: Qian Zhang, et al.
Published: (2023-02-01)

Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review
by: Yuxuan Hao, et al.
Published: (2022-08-01)

Incidence and outcome of immune checkpoint-induced pneumonitis in oncology patients with history of pulmonary disease
by: Emily Allen, et al.
Published: (2023-10-01)

Development and Validation of a Radiomics Nomogram Using Computed Tomography for Differentiating Immune Checkpoint Inhibitor-Related Pneumonitis From Radiation Pneumonitis for Patients With Non-Small Cell Lung Cancer
by: Qingtao Qiu, et al.
Published: (2022-04-01)

Risk of Pneumonitis Associated With Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Network Meta-Analysis
by: You-Meng Sun, et al.
Published: (2021-10-01)

Surrogate endpoints for overall survival in randomized clinical trials testing immune checkpoint inhibitors: a systematic review and meta-analysis
by: Isabella Sala, et al.
Published: (2024-01-01)

Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis
by: Qiang Su, et al.
Published: (2019-02-01)

Radiation Recall Pneumonitis Induced by Sintilimab: A Case Report and Literature Review
by: Min Wang, et al.
Published: (2022-02-01)

Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis
by: Chuzi S, et al.
Published: (2017-06-01)

Risk factors for pneumonitis in advanced extrapulmonary cancer patients treated with immune checkpoint inhibitors
by: Yasuki Uchida, et al.
Published: (2022-05-01)

A retrospective study on immune-related pneumonitis in patients with non-small-cell lung cancer undergoing treatment with PD-1/PD-L1 inhibitors
by: Dorthe Yakymenko, et al.
Published: (2023-01-01)

Case report: Pneumonia with clinical symptoms precedes imaging evidence after immune checkpoint inhibitors combined with radiotherapy in lung squamous cell cancer
by: Yao Wang, et al.
Published: (2022-09-01)

The Clinical Analysis of Checkpoint Inhibitor Pneumonitis with Different Severities in Lung Cancer Patients: A Retrospective Study
by: Hui Huang, et al.
Published: (2024-01-01)

Predictive factors and prognosis of immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer patients
by: Xiaoyu Liu, et al.
Published: (2023-04-01)

Research Progress of Biomarkers for Immune Checkpoint Inhibitors on Digestive System Cancers
by: Jingting Wang, et al.
Published: (2022-04-01)

Regulatory T-Cells as an Emerging Barrier to Immune Checkpoint Inhibition in Lung Cancer
by: Daniel R. Principe, et al.
Published: (2021-06-01)

Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management
by: Qin Zhang, et al.
Published: (2021-05-01)

Clinical outcomes and risk factor of immune checkpoint inhibitors-related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary disease
by: Zhu Zeng, et al.
Published: (2022-12-01)

Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC
by: Joshua E. Reuss, MD, et al.
Published: (2021-10-01)

Prognostic Biomarker TP53 Mutations for Immune Checkpoint Blockade Therapy and Its Association With Tumor Microenvironment of Lung Adenocarcinoma
by: Xinqing Lin, et al.
Published: (2020-11-01)

Pulse corticosteroid therapy in the treatment of steroid-refractory immune checkpoint inhibitor-related pneumonitis: Case report and review
by: Kuan-Chang Lai, et al.
Published: (2022-08-01)

Cardiotoxicity induced by immune checkpoint inhibitor: The complete insight into mechanisms, monitoring, diagnosis, and treatment
by: Sridha Ganesh, et al.
Published: (2022-09-01)